NN-2211 Novo Nordisk.
Novo Nordisk A/S, under license from Scios Inc, is developing NN-2211, a stable analog of the naturally occurring peptide hormone glucagon-like peptide 1 (GLP-1), which stimulates insulin release in response to increases in blood sugar levels, for the potential treatment of type 2 diabetes.
Mark
Michael
M
Boehringer Ingelheim Pharma GmbH & Co KG, Department of Metabolic Research, Birkendorfer Strasse 65 88397, Biberach an der Riss, Germany. michael.mark@bc.boehringer-ingelheim.com
D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism; D005934:Glucagon / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D006801:Humans; D000069450:Liraglutide; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*
D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon